Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapeutics that modify the course of cardiopulmonary diseases, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s lead product candidate is IKT-001, an oral prodrug of imatinib designed to inhibit type III receptor tyrosine kinases implicated in PAH pathology. IKT-001 aims to improve hemodynamic function and exercise capacity while offering a…
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapeutics that modify the course of cardiopulmonary diseases, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s lead product candidate is IKT-001, an oral prodrug of imatinib designed to inhibit type III receptor tyrosine kinases implicated in PAH pathology. IKT-001 aims to improve hemodynamic function and exercise capacity while offering a potentially better tolerability profile compared with parent imatinib. The company holds global commercialization rights to IKT-001 and has secured patent protection in the United States extending to 2039, with possible extension to 2044.
We generate revenue primarily through licensing agreements and potential milestone payments from partners. Under a license agreement with ABLi Therapeutics, Inc. we are eligible to receive development and regulatory milestone payments up to $47.5 million and double digit royalty payments on net sales of the licensed product risvodetinib. Additionally, we may receive revenue from other collaborative arrangements and future commercialization of IKT-001 upon regulatory approval.
In the pulmonary arterial hypertension market, Inhibikase Therapeutics, Inc. positions itself as a developer of a disease modifying therapy that targets the type III receptor tyrosine kinase pathway, a mechanism distinct from the vasodilator focus of most approved treatments. Competitors include established therapies such as endothelin receptor antagonists, phosphodiesterase five inhibitors, prostacyclin analogs, and newer agents like sotatercept (WINREVAIR) from Merck and Co. The company’s competitive advantages stem from the oral administration of IKT-001, its potential to improve tolerability by reducing gastrointestinal side effects, and its strong intellectual property portfolio with patent protection extending to 2039. Additionally, the drug’s mechanism may address vascular remodeling, offering a possible disease modifying benefit that many current therapies do not provide.
Although the company has not yet commercialized a product, its intended customer base includes patients with pulmonary arterial hypertension, treating physicians such as pulmonologists and cardiologists, specialized treatment centers, and healthcare payors that may provide coverage and reimbursement for approved therapies.